TABLE 1.
Anterior chamber flare before and 1 day and 1 month after each intravitreal bevacizumab injection.
| n° (eyes) | Anterior chamber flare (photons/ms) | p | ||||||
|---|---|---|---|---|---|---|---|---|
| Min | Max | Mean | SD | Median | ||||
| Before treatment | 48 | 3.5 | 18.2 | 7.51 | 3.42 | 6.70 | ||
| 1 day after 1st injection | 47 | 2.9 | 16.1 | 7.34 | 3.18 | 6.80 | 0.738 | |
| 30 days after 1st injection | 46 | 1.0 | 17.0 | 7.07 | 3.26 | 6.40 | 0.419 | |
| 1 day after 2nd injection | 47 | 3.2 | 16.9 | 8.03 | 3.07 | 7.10 | 0.419 | |
| 30 days after 2nd injection | 41 | 2.6 | 27.1 | 7.74 | 4.24 | 6.80 | 0.842 | |
| 1 day after 3rd injection | 38 | 2.7 | 22.5 | 7.60 | 3.86 | 6.50 | 0.882 | |
| 30 days after 3rd injection | 48 | 3.1 | 17.2 | 6.98 | 2.62 | 6.60 | 0.333 | |
Min, minimum value; max, maximum value; SD, standard deviation; p, p value: p-values estimated with linear mixed-effects model.